FDA Adds Safety Warnings to SGLT2 Inhibitor Labels

Drug GMP Report
Following a safety review, the FDA has added additional warnings to the labels of SGLT2 inhibitors for diabetes because they can cause the body to produce too much acid in the blood or lead to serious urinary tract infections.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00